A Phase 1/2 interventional study of LYT-300 and Placebo in Healthy Volunteers, sponsored by PureTech. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by PureTech · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300.
Part 2 is a crossover assessment in HV of the effects of food on the safety, tolerability, and PK profile of orally administered LYT-300.
Part 3 is a multiple ascending dose (MAD) trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300.
Part 4 is an assessment of the effects of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.
Part 1: This is a randomized, double-blind, placebo-controlled, SAD design to assess the safety, tolerability, and PK profile of orally administered LYT-300 in HV, in a 3-period, 3-sequence, crossover, dose escalation design.
Part 2: This is a randomized, open label, 3-period, 3-sequence, crossover assessment of the effects of food on the PK, safety, and tolerability of orally administered LYT-300 in HV. A single dose of LYT-300 will be administered on 3 occasions, separated by a minimum 7-day washout period. Part 2 is planned as a single dosing cohort.
Part 3: This is a randomized, double-blind, placebo-controlled, sequential, MAD trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300. This part will include ascending doses given either once daily in the morning (QAM), once daily in the evening (QHS), or twice daily (BID).
Part 4: This is a double-blind, randomized assessment of the effects in HV of a single dose of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Parts 1, 2, 3 and 4: Healthy Volunteers
Main Exclusion Criteria:
Parts 1, 2, 3 and 4: Healthy Volunteers
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
Drug: LYT-300 · Other: Placebo
LYT-300, Dose TBD with and without food, separated by 7-day washout
Drug: LYT-300
Drug: LYT-300
Other: Placebo
Drug: LYT-300 · Other: Placebo
Drug: LYT-300 · Other: Placebo
Drug: LYT-300
Other: Placebo
A prodrug of allopregnanolone, a small molecule drug
Placebo for LYT-300
Safety and tolerability: treatment-emergent adverse events [TEAEs]
Evaluate the safety and tolerability in healthy volunteers following single or multiple oral doses of LYT-300 as measured by TEAEs.
Time frame: 7 days (main time frame)
Effect of food in healthy volunteers
Measure concentration of allopregnanolone in blood plasma in fed or fasted subjects administered a single dose of LYT-300
Time frame: 2 days (main time frame)
Salivary cortisol
Change in salivary cortisol
Time frame: 60 minutes
Use pharmacokinetics to characterize the blood plasma concentration of allopregnanolone after administration of LYT-300
Measure the blood plasma concentrations of allopregnanolone in healthy volunteers after single and multiple doses of LYT-300 administered up to 7 days
Time frame: 7 days (main time frame)
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Oct 2023, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PureTech